Delving into the Latest Updates on HZ-010 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Target

Mechanism

GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Zhejiang Heze Pharmaceutical Technology Co., Ltd.

Active Organization

Zhejiang Better Pharmaceuticals Co. Ltd.

Zhejiang Heze Pharmaceutical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： 1、通过健康受试者单次皮下注射浙江和泽医药科技股份有限公司研发的HZ010，考察HZ010的安全性和耐受性，为后续临床试验剂量选择提供参考依据； 2、通过健康受试者多次皮下注射浙江和泽医药科技股份有限公司研发的HZ010，考察HZ010的安全性和耐受性，为后续临床试验剂量选择提供参考依据。次要目的：考察HZ010在健康受试者体内单次给药和多次给药的药代动力学特征以及多次给药后药效学特征。

[Translation]

Main purpose: 1. To investigate the safety and tolerability of HZ010 developed by Zhejiang Heze Pharmaceutical Technology Co., Ltd. by single subcutaneous injection in healthy subjects, and provide a reference for the dose selection of subsequent clinical trials; 2. To investigate the safety and tolerability of HZ010 developed by Zhejiang Heze Pharmaceutical Technology Co., Ltd. by multiple subcutaneous injection in healthy subjects, and provide a reference for the dose selection of subsequent clinical trials. Secondary purpose: To investigate the pharmacokinetic characteristics of HZ010 after single and multiple administrations in healthy subjects, and the pharmacodynamic characteristics after multiple administrations.

Start Date17 Nov 2022

Sponsor / Collaborator

Zhejiang Heze Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with HZ-010

Login to view more data

100 Translational Medicine associated with HZ-010

Login to view more data

100 Patents (Medical) associated with HZ-010

Login to view more data

100 Deals associated with HZ-010

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	CN	Zhejiang Better Pharmaceuticals Co. Ltd.	17 Nov 2022
Diabetes Mellitus, Type 2	Phase 1	CN	Zhejiang Heze Pharmaceutical Technology Co., Ltd.	17 Nov 2022